Informa extends open access position and capability with addition of Dove Medical Press
- Open Access expansion…Addition of independent open access (“OA”) publisher, Dove Medical Press, increases Informa’s position and capability in the growing OA market
- Quality journal portfolio…Collection of established and indexed journals takes Informa’s OA journal portfolio to over 200 and total number of journals to more than 2,500;
- Platform capability…Established platform for identifying new subject categories, managing collaboration and peer review
- Attractive fit …Strengthens position in Health Sciences, including growth subjects such as oncology, ophthalmology, neuroscience and psychiatry
London: Informa (LSE: INF.L), the International Exhibitions, Events, Business Intelligence and Academic Publishing Group, today announces the addition of Dove Medical Press, strengthening its capability and presence in open access publishing.
Stephen A. Carter, Informa Group Chief Executive, said: “The addition of Dove Medical Press adds strength and capability to our OA portfolio, further increasing choice and flexibility for researchers across a widening range of subject areas.”
He added: “Its track record, publishing platform and growing reputation in Health Sciences enhance our Journals business, strengthening our position in the attractive and growing OA market.”
Dove Medical Press is an independent OA journals publisher, founded in 2003, producing a range of quality OA journals, mainly in Health Sciences, with additional content in Science and Technology. A large proportion of its journals are indexed by the Web of Science and PubMed and a growing number have established and improving impact factors. Leading titles include OncoTargets and Therapy, International Journal of Nanomedicine and Clinical Ophthalmology.
The addition of Dove Medical Press complements our growing portfolio of OA titles published under the Taylor & Francis and Cogent brands, enabling continued expansion in the attractive OA market. Following the acquisition, Informa will publish more than 200 OA journals, as part of a total journal portfolio of more than 2,500 titles, providing a valuable and growing alternative publishing outlet for authors.
Financial details were not disclosed but the transaction is expected to be modestly accretive to adjusted earnings in the first full year of ownership and deliver a return on investment ahead of the cost of capital within three years.
Tim Burt / Zoe Watt at Teneo Blue Rubicon on +44 (0) 20 7240 2486
Informa Group PLC
Informa is a leading international Business Intelligence, Exhibitions, Events and Academic Publishing Group with annual revenues of over £1.6bn. It helps commercial, professional and academic communities work smarter and make better decisions faster, through specialist content and intelligence, and opportunities to connect and learn.
Dove Medical Press, Ltd
Dove Medical Press Ltd is a privately held company specializing in the publication of Open Access peer-reviewed journals across the broad spectrum of science, technology and especially medicine. Dove Press was founded in 2003 with the objective of combining the highest editorial standards with the 'best of breed' new publishing technologies. Dove Press has offices in Manchester and London in the United Kingdom, representatives in Princeton, New Jersey in the United States, and editorial offices in Auckland, New Zealand. See more at http://www.dovepress.com